11.20.2013

The BIO Investor Forum is an international biotech investor conference focused on early and established private companies as well as emerging public companies. The event features plenary sessions, business roundtables, therapeutic workshops, fireside chats, company presentations, and One-on-One Partnering™ meetings. Overall attendance was up 28 percent, and investor attendance was up 14 percent over last year.


CONFERENCE SPECIAL REPORT The BIO Investor Forum The 12th Annual BIO Investor Forum featured exciting panels, partnering meetings and more! We had nearly 600 attendees, including 167 qualified investors and 27 reporters. We hosted over 900 One-on-One Partnering™ meetings, directly connecting senior company executives with prospective partners and investors... Share: FIRESIDE CHAT Fireside Chat with Jan M. Lundberg, PhD, President, Lilly Research Laboratories Want to see more in-depth interviews with CEOs of the world’s top biophrama companies? Register for the 2014 CEO & Investor Conference February 10-11 in New York City, and hear candid discussions between biopharma CEOs and Wall Street analysts. Hear about recent company successes, what keeps the C-suite up at night, and where the industry’s leading companies are headed in 2014... Share: biotech IPO Lots of Buzz at the BIO Investor Forum Nearly 600 biotech industry leaders, investors, and reporters gathered in San Francisco to find business partners, make connections, and hear our panelists... Share: BIO InVESTOR FORUM BIO Investor Forum Kicks Off Amid Industry Optimism The BIO Investor Forum kicks off in San Francisco, Calif. BioWorld’s Catherine Shaffer paints a positive picture of the industry highlighting the strong IPO activity and heightened interest in the sector among investors... Share: PARTNERSHIPS Successful Public-Private Partnerships According to BayBio, biomedical companies that can harness the power of patient groups will get medicines, devices and diagnostics to market faster, cheaper and smarter, helping patients and rewarding investors... Share: INVESTMENT Biotech IPO Boom or Bubble? The Opening Plenary at the BIO Investor Forum With 31 (and counting) life sciences companies having already placed IPOs on the market within the first 8 months of this year and many others lining up for S-1 filings, biotech is buzzing about a revival of the IPO market... Share: JOBS ACT The New Road to IPO in the Age of the JOBS Act Not surprisingly, sessions discussing the topic of IPOs at this year’s BIO Investor Forum, tend to fill the room. Furthermore, it should surprise no one that this year’s IPO discussions were upbeat... Share: funding Crowdfunding in Health Care and Biotechnology Crowdfunding has been used in a limited number of examples for life sciences companies, but where is this pathway heading? How should a company look at opportunities for crowdfunding? Share: GAIN ACT GAIN Act: A Great First Step Given the growing threat posed by resistant bacteria, we decided to hold a workshop with leading experts about what effect the GAIN Act might have to incentivize antibiotic development... Share:		UPCOMING EVENTS 02.10.14 BIO CEO & Investor Conference With 1380 partnering meetings and nearly 700 investors in attendance last year, the 2014 BIO CEO & Investor Conference in New York City, February 10-11, is sure to provide you with the high growth opportunities you need. Don’t miss registering today... REGISTER 11.18.13 BioSafe Meetings The meeting's goal is to provide industry experience and perspectives gained to help ensure common understanding and continued application of scientific principles with respect to key issues in preclinical safety evaluation of biopharmaceuticals... REGISTER 12.08.13 Pacific Rim Summit on Industrial Biotechnology & Bioenergy The Pacific Rim Summit on Industrial Biotechnology and Bioenergy is the original conference dedicated solely to the growth of the industrial biotechnology and bioenergy sectors in North America and the Asia-Pacific region... REGISTER 04.8.14 BIO Asia International Conference The BIO Asia International Conference is an exclusive, customized partnering forum that brings together U.S. and European drug development companies with Asian biotech and pharmaceutical companies... SAVE THE DATE ON Twitter.COM/#BIF13 Overhead at #BIF13. 'Can U believe we're still standing at the podium and pitching after all these years? Where did we go wrong?" — @ldtimmerman 1 Retweet Paul Hastings: we have potential to improve in industry w/ more data transparency abt drug failures. #BIF13 Not a popular line in pharma —@ldtimmerman Orphan approach will be sustainable, says Esperion's Andreach, if "It's the right patient with the right drug for the right disease." #BIF13 —@BioWorld 5 Retweets Not investing in NIH is silly, stupid and industry should be active, vocal and concerned about cuts. - Borisy #BIF13 — @Rrleuty_Biotech 4 Retweet Primary care panel weighs in on ACA. Its impact will be "evolutionary rather than revolutionary," says NEA's Mathers. #BIF13 — @BioWorld 2 Retweets Good stuff @IAmBiotech: here's a great summary from the plenary http://ow.ly/pEsZO — @IamBiotech 5 Retweets Jan Lundberg: Bright people like to be around other bright people. You must have high standards. Give people freedom to operate, fail #BIF13 — @ldtimmerman 2 Retweets